Premium
Insulin degludec overdose may lead to long‐lasting hypoglycaemia through its markedly prolonged half‐life
Author(s) -
Uchida J.,
Oikawa Y.,
Katsuki T.,
Takeda H.,
Shimada A.,
Kawai T.
Publication year - 2018
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.13557
Subject(s) - medicine , insulin degludec , insulin , diabetes mellitus , level of consciousness , anesthesia , hypoglycemia , endocrinology , insulin glargine
Background Overdose of insulin often causes long‐lasting severe hypoglycaemia. Insulin degludec has the longest duration of action among the available insulin products; thus, an overdose of insulin degludec can lead to long‐lasting hypoglycaemia. In the present paper, we report the case of a woman with long‐lasting hypoglycaemia attributable to insulin degludec overdose and markedly prolonged insulin degludec half‐life. Case report A 64‐year‐old woman with Type 2 diabetes receiving insulin therapy was taken to an emergency department because of disturbed consciousness 21 h after self‐injection of 300 units of insulin degludec (4.34 units/kg). Her plasma glucose level was 2.3 mmol/l. She received repeated intravenous boluses of dextrose for 43 h with continuous intravenous dextrose infusion, but no improvement in long‐lasting hypoglycaemia or consciousness was observed. Considering the possibility of adrenal insufficiency, intravenous dexamethasone was administered, and her plasma glucose levels subsequently remained above 5.5 mmol/l without intravenous dextrose boluses. She gradually regained consciousness. A total of 34 h after the overdose, her plasma immunoreactive insulin levels were markedly increased and then gradually declined over ~400 h. The insulin degludec half‐life was 40.76 h. Conclusion Although the reported half‐life of insulin degludec in the body is ~25 h when administered in standard doses (0.4–0.8 units/kg), no study has investigated its half‐life after overdose. In the present case, the half‐life of insulin degludec was ~1.6 times longer than that observed with standard doses, probably leading to long‐lasting hypoglycaemia. Physicians should be aware of the possibility of unexpected long‐lasting severe hypoglycaemia resulting from insulin degludec overdose.